Rankings
▼
Calendar
KLRS Q3 2021 Earnings — Kalaris Therapeutics Inc Revenue & Financial Results | Market Cap Arena
KLRS
Kalaris Therapeutics Inc
$180M
Q3 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$44,000
Operating Income
-$46M
Net Income
-$46M
EPS (Diluted)
$-16.62
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$36M
Free Cash Flow
-$36M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$317M
Total Liabilities
$49M
Stockholders' Equity
$267M
Cash & Equivalents
$243M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
-$44,000
-$18,000
-144.4%
Operating Income
-$46M
-$24M
-90.4%
Net Income
-$46M
-$24M
-92.7%
← FY 2021
All Quarters
Q4 2021 →